Google Updates Policy to Allow CBD Advertising in Select Markets

Jan.11.2023
Google Updates Policy to Allow CBD Advertising in Select Markets
Google allows ads for marijuana and topical CBD products in California, Colorado and Puerto Rico, and FDA-approved drugs.

Google has updated its policies on "dangerous products and services, as well as healthcare and drugs," allowing advertisements for marijuana and topical CBD products to be promoted in California, Colorado, and Puerto Rico in the United States.


Google did not provide a clear explanation for why it is limiting ads in these three distinct markets.


The company stated that CBD advertisements for entertainment products are still subject to limitations, including "supplements, food additives and inhalants." Additionally, according to policy revisions, header ads on YouTube (owned by Google) appear at the top of the main homepage on all devices and do not apply to marijuana and CBD products.


Google also stated that drugs approved by the Food and Drug Administration (FDA) can now be advertised in these jurisdictions. This rule change will only benefit one manufacturer, Jazz Pharmaceuticals, whose high-CBD Epidiolex is the only product of its kind that the agency has approved to date. Epidiolex is used to treat severe seizures in children and was approved by the FDA in 2020.


These changes were announced at the end of the year and will take effect on January 20th. Advertisers can start applying for Google certification from that date and the application form will be released.


Google has announced that it has signed a contract with LegitScript, an internet and payment compliance company based in Portland, Oregon. LegitScript provides certification in high-risk industries and serves as a credential exchange for determining product advertising eligibility. Only products certified by LegitScript are permitted to be promoted on the Google platform.


According to Google, individuals seeking to advertise on the platform must provide their product samples or THC tests, and provide third-party analysis certificates to LegitScript for verification.


In an industry where contaminated, substandard, or illegal products are still prevalent, it is more important than ever to assure consumers that the CBD products they are purchasing have undergone proper scrutiny," said Scott Ross, CEO of LegitScript.


This internet giant appears to be unnerved by the prospect of continuing to use CBD products internally. Such products have received warnings from the FDA, as various studies have shown contamination by solvents and heavy metals among other impurities. Delta-8 THC derived from cannabis produced via synthetic processes has been implicated in the death of a child in Virginia last year.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Philip Morris Japan (PMJ) began launching three IQOS ILUMA i BEYOND limited-edition heated tobacco devices in Japan on November 18, 2026, covering PRIME, the standard ILUMA i and ONE. Suggested retail prices are ¥11,980, ¥7,980 and ¥4,980, respectively, matching the REMIX limited-edition collection introduced in June. BEYOND features blue finishes, translucent components and differentiated surface materials while retaining the existing IQOS ILUMA i device architecture. As with REMIX, all three models are available through official and specialist retail channels, while the subsequent convenience store rollout covers only the standard ILUMA i and ONE versions. The two collections share the same pricing tiers and retail distribution structure, with their principal differences in exterior design.
product
Nov.20
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24